{"id":687979,"date":"2022-09-22T08:05:37","date_gmt":"2022-09-22T12:05:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/"},"modified":"2022-09-22T08:05:37","modified_gmt":"2022-09-22T12:05:37","slug":"pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/","title":{"rendered":"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference"},"content":{"rendered":"
\n

FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will participate on a panel at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference being held at the Lotte New York Palace Hotel in New York City on September 28, 2022.<\/p>\n

\n Cantor Fitzgerald\u2019s Oncology & HemOnc Conference <\/strong>
\n
Date: Wednesday, September 28, 2022
Time: 1:45 PM EDT
Panel: Trends and Challenges in Immuno-Oncology<\/p>\n

For more information about the conference, or to schedule a one-on-one meeting with PDS Biotech management, please contact your Cantor representative directly, or send an email to pdsb@cg.capital.<\/p>\n

\n About PDS Biotechnology<\/strong>\n <\/p>\n

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune\u00ae<\/sup> and Infectimune\u2122 T cell-activating technology platforms. We believe our targeted Versamune\u00ae<\/sup> based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune\u00ae<\/sup> clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials. Our Infectimune\u2122 based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.<\/p>\n

Versamune\u00ae<\/sup> is a registered trademark and Infectimune\u2122 is a trademark of PDS Biotechnology.<\/p>\n

\n Investor Contacts:<\/strong>
\n
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
drandolph@pdsbiotech.com<\/a><\/p>\n

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital<\/a><\/p>\n

\n Media<\/strong>
\n
Dave Schemelia
Tiberend Strategic Advisors, Inc.<\/a>
Phone: +1 (609) 468-9325
dschemelia@tiberend.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will participate on a panel at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference being held at the Lotte New York Palace Hotel in New York City on September 28, 2022. Cantor Fitzgerald\u2019s Oncology & HemOnc Conference Date: Wednesday, September 28, 2022Time: 1:45 PM EDTPanel: Trends and Challenges in Immuno-Oncology For more information about the conference, or to schedule a one-on-one meeting with PDS Biotech management, please contact your Cantor representative directly, or send an email to pdsb@cg.capital. About PDS Biotechnology … <\/p>\n

Continue reading “PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687979","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will participate on a panel at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference being held at the Lotte New York Palace Hotel in New York City on September 28, 2022. Cantor Fitzgerald\u2019s Oncology & HemOnc Conference Date: Wednesday, September 28, 2022Time: 1:45 PM EDTPanel: Trends and Challenges in Immuno-Oncology For more information about the conference, or to schedule a one-on-one meeting with PDS Biotech management, please contact your Cantor representative directly, or send an email to pdsb@cg.capital. About PDS Biotechnology … Continue reading "PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T12:05:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference\",\"datePublished\":\"2022-09-22T12:05:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/\",\"name\":\"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=\",\"datePublished\":\"2022-09-22T12:05:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference - Market Newsdesk","og_description":"FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will participate on a panel at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference being held at the Lotte New York Palace Hotel in New York City on September 28, 2022. Cantor Fitzgerald\u2019s Oncology & HemOnc Conference Date: Wednesday, September 28, 2022Time: 1:45 PM EDTPanel: Trends and Challenges in Immuno-Oncology For more information about the conference, or to schedule a one-on-one meeting with PDS Biotech management, please contact your Cantor representative directly, or send an email to pdsb@cg.capital. About PDS Biotechnology … Continue reading \"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T12:05:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference","datePublished":"2022-09-22T12:05:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/"},"wordCount":327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/","name":"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=","datePublished":"2022-09-22T12:05:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTA2MSM1MTY1NDY4IzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-to-participate-at-cantor-fitzgeralds-oncology-hemonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotech to Participate at Cantor Fitzgerald\u2019s Oncology & HemOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687979"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687979\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}